Navigation Links
The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
Date:9/9/2008

Summary: Protein Tomography(TM) has yet Again Provided Structural Proof of a Drug Target Function. A Study Performed by Sidec and UCB, Characterizes the Target of Anti-Epileptic Drug in Situ Where Two Major Conformations

Have Been Identified

STOCKHOLM, September 9 /PRNewswire/ -- Sidec AB has together with UCB published the first direct structural evidence of the molecular mechanism of the Synaptic Vesicle protein 2A (SV2A) in mouse brain tissue. SV2A is the unique brain-binding site of the second generation anti-epileptic drug levetiracetam (LEV; Keppra(R) is a trademark of UCB). The result shows the first direct structural proof of the "alternating access model" that has been proposed for the MFS class of transporter proteins. The "alternating access model" postulates that the trans-membrane MFS class proteins can exist in two different conformations; as a valve that can be open to either side of the membrane. Prior to this Protein Tomography(TM) study, great efforts were made to prove this mechanism both by x-ray crystallography and indirectly by site directed mutagenesis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

"Obtaining structures of trans-membrane proteins is notoriously difficult, and the success of such endeavours is difficult to predict. This study demonstrates that Protein Tomography(TM) is well adopted to study structure, function and flexibility of trans-membrane proteins," says Anders Aberg, CSO at Sidec.

The publication is available on-line in the journal Biochemical and Biophysical Research Communications, August 7, 2008. http://www.elsevier.com/locate/ybbrc

About Sidec:

Sidec offers Protein Tomography((TM)) as collaborative contract research projects. The multidisciplinary team of experts at Sidec can provide a strong IP strategy and proven product differentiation to the bio-pharmaceutical industry. Sidec offers their partners a unique visual guidance for target- lead and CD selection to secure a competitive advantage in the drug design strategy. More information can be found on our homepage where we continuously update academic collaborations and industrial partnerships as well as recent publications.

For more information, please contact:

Mr. Hans Johansson, CEO

Phone: +46(8)560-02-102

E-mail: hans.johansson@sidec.com

http://www.sidec.com


'/>"/>
SOURCE Sidec AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... Bio-Ess Laboratories, LLC Chief Science Officer, Dr. Adam Elhofy ... data on Cell-Ess® Universal Titer Boost at the 9 th ... August 21-25.  The Bioprocessing Summit convenes more than 1,000 international bioprocess ... ... Cell-Ess ...
(Date:8/15/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO), is now ... residents. Naloxone is available without a ... pharmacy, G-3320 Beecher Road. ... Administration, is intended to block or reverse the effects ... of consciousness. The medication is often carried by first ...
(Date:8/15/2017)... N.C. , Aug. 15, 2017 AccuGenomics, ... NC , today announced that the company has ... the University of North Carolina at Chapel Hill and ... is designed to characterize and quantify HIV reservoir and ... after pharmacological intervention. The HIV Cure Center is a ...
Breaking Medicine Technology:
(Date:8/20/2017)... ... August 20, 2017 , ... Are you an adult ... If so, you may be interested in participating in a research study that ... research is to understand more about the relational aspects of adults who have gluten ...
(Date:8/19/2017)... (PRWEB) , ... August 19, 2017 , ... ... announced that it is the first organization with pending recognition status from the ... Prevention Program (“DPP”) via group telehealth classes and live video conferencing. , ...
(Date:8/19/2017)... ... August 19, 2017 , ... Physician Partners of America ... as an interventional pain management physician. He brings a wealth of pain management ... headaches, and significant experience in spinal cord stimulation for chronic pain. , Dr. ...
(Date:8/18/2017)... ... August 18, 2017 , ... ... specialized asset-light logistics provider of complex transport solutions for mission-critical and non-discretionary ... Unitrans International Corporation, a division of Roadrunner Transportation Systems, Inc. (NYSE: RRTS). ...
(Date:8/18/2017)... ... ... The Dawn Johnson Insurance Group, a Missouri-based insurance and financial planning firm ... for efforts to educate the local population on cancer realities while attracting donations to ... , Each day in America, roughly 4,600 new cases of cancer are diagnosed and ...
Breaking Medicine News(10 mins):